Seeking Alpha

jo103

jo103
Send Message
View as an RSS Feed
View jo103's Comments BY TICKER:
Latest  |  Highest rated
  • BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug [View article]
    I wanted to know whether you are holding shares of blrx.
    And what do you think you will be in shares up to 17/3
    Feb 2, 2013. 07:58 AM | Likes Like |Link to Comment
  • BioLineRx: Upside Greater Than Stated By Analyst [View article]
    Long ago I said that the price is not applicable for today
    Jul 6, 2012. 05:31 AM | Likes Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    If the break in arrives. Cycle about half from the average and this after C70 minutes.
    Jul 13, 2010. 10:18 AM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    If rite 2 tell that/because Bcypb created support B2.16. I think that/because there is collect in share already several days. cycle today high 1.4 million shares & he's continuation of rise in cycles in last period.
    Jul 12, 2010. 04:25 PM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    Which big cycle there is momentarily this Bcypb. If is done a collection upwards and later collection from down.
    Jul 12, 2010. 12:13 PM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    Israel's BioLineRx readies Nasdaq share offer

    Digg This Tweet ThisShare on LinkedIn Share on FacebookStocks
    BioLineRX Ltd.
    BLRX.TA
    359.00₪
    +18.00+5.36%9:20am UTC+0300
    TEL AVIV | Mon Jul 12, 2010 2:47am EDT

    TEL AVIV July 12 (Reuters) - Israeli drug development company BioLineRx (BLRX.TA) is planning a share offering on U.S. exchange Nasdaq, the company said on Monday.

    BioLineRx said its board has decided to advance the process and has called a shareholders' meeting to approve certain measures that must be taken.

    The company has already started preparations for an offering and submitted confidential filings to the U.S. Securities and Exchange Commission, BioLineRx said in a statement to the Tel Aviv Stock Exchange.

    The next filing is expected to be public, it added.

    "It should be clear that the timing, size and structure of the offering have not been finalised," the statement said.

    BioLineRx signed a $365 million out-licensing deal last month with Cypress Bioscience (CYPB.O) for its anti-psychotic drug BL-1020. [ID:nLDE65J03G]

    Last year New Jersey-based Ikaria Holdings Inc agreed to pay $285 million for a license to develop and market BioLineRx's BL-1040 drug for heart attack patients. [ID:nL6111104]

    BL-1040 is a myocardial implant for the treatment of acute myocardial infarction.

    (Reporting by Tova Cohen; Editing by Michael Shields)
    Jul 12, 2010. 03:45 AM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    In their Julies lurked Aks ltd. ( " the company " ) 12.7.2010 re : Progress in the process to the issue in Nasdaq the company informs in this that/because on day 11.7.2010 decided a directorate of the company to progress in the process to her shares issues of the company and their registering to the commerce by the stock exchange of the Nasdaq that in United States and in this respect to summon an assembly by and large for approval of number of subordinate actions to registering as mentioned. Invitation to the aforesaid served assembly in tandem to this report. Will be marked that/because the company began this already to prepare/take place/ to the process of the issue and in this frame submitted to the authority of securities Hamrikanit from supports of registering in the way is not public when the company of observer that/because document of the next registering will be served in the public way. (Confidential filings ) will be elucidated that/because timing of the issue, her extent and her structure not yet were determined in the final way. More will be elucidated that/because this report does not constitute an offer of sold, offer to the public to acquire or coaxing to the acquisition of securities. Intention of of the company to offer Mniotia to the public in United States as mentioned is information of observer of face of future as his definition in the law of securities, Htshc"h 1968 the based on the present expectations of the company. His materialization is likely or at all of the information is influenced from factors which it's impossible Lharicm in advance and they are not found controled by the company, to the multifactor the risk that characterize activity of the company and situation of market of the securities in United States. Sincerely, in their Julies lurked Aks ltd.

    This announcement to the stock exchange from today. They execute an union of shares 10 for 1. I am a holder since yesterday certain amount by the options of the company. My question is. If allowable to issue Bnsd"k when to the obligated ' there are options...
    Jul 12, 2010. 02:31 AM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    Exploits the momentum : In their Julies from hurry process of her issue in Nasdaq for bizportal well known that/because in the last week of general manager of the company DR. Kinneret Soitski lingered in United States and meets with underwriters permute Kornpld22:01 | 11.07.10 added warning of the past to connect printing rss! Add Lfacebook added Ltwitter updates are warmish and warnings joined us in Facebook followed after us in the tweeter always up to date also in the cellular all the data in real time the company of development of the medicines in their Julies ( 354 | 5.36% ) from hurry process of the issue of the company in Nasdaq, so well known for bizportal. In the last week of general manager of the company DR. Kinneret Soitski lingered in United States and according to the sets meet with potential underwriters that will lead the issue. In the company in their Julies want to exploit the business positive momentum in which situated the company, this after only before three weeks signed the company on deal Lmshor the medicine to the schizophrenia that developed the company ( bl1020 ) with the company Siprs the American. Agreement has a potential of earnings of 365 million dollar. In spite of the positive agreement and the preliminary payment in the extent of 30 million dollar the same she is supposed to receive, in the capital market did not receive the deal positively, among other things on background of the sharp parachuting in the price shares of Siprs. Shares of the American company dropped in/by almost 50% from moment of the declaration on the deal to the value of about 82.1 million dollar. In a similar vein, shares of in their Julies intersect in about 20%, but it is important to point out that/because not yet publication of the deal of the capacity the her Menis to climb the similar rate/lesson. Publication at least for the time being, considerable that/because Bbiolin not really need the cashes, and this inasmuch as that in the end of the first quarter were in the fund of the company about 95 million shekel, amount that not includes in him/it payment of the preliminary grant him likely to receive the company Msiprs. Already before half year, in the end 2009, tested in the company Hbiomd the issue of the company in Nasdaq. Then stood its value of in their Julies on 140 million dollar and according to the reports in the communication of the company examined enlistment according to value more high. At this time, its value of in their Julies stand on 113 million dollar only, almost 30 million this inferior dollar in spite of the progress are business the company. According to the sets, in the company believe at this time that the attractive pricing of the company in United States will help promote the issue rapidly.
    Jul 11, 2010. 03:27 PM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    Biolinerx rose B3 the last days 8% after recovered from the deal of Hmishor. Today she rose B5% with big cycle. It is about time that also my investor cypb they will understand the deal that is good this. Why the investors Busa don't understand the potential B1020
    Jul 11, 2010. 10:06 AM | 1 Like Like |Link to Comment
  • 8 STRONG BUYS => Rx Investors.com [View instapost]
    Entered Lcypb in the average gate of 2.16$ after the deal with byolain.... Pleasant inker to recognize. The writing became by means of translation on the internet thank you

    yosef2006@013.net
    Jul 10, 2010. 09:36 AM | 1 Like Like |Link to Comment
COMMENTS STATS
10 Comments
8 Likes